Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
Chinese Cars in Europe: Consumer Trust Is Shifting Fast 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
Chinese Brands Are Taking Over Brazil — And It's Just Getting Started 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
SALT LAKE CITY, Aug. 30, 2017 -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced today that Mark C. Capone, president and CEO, is scheduled to present at the Morgan Stanley Global Healthcare Conference at 10:35 a.m. ET on September 12, 2017, at the Grand Hyatt New York in New York City.
The presentation will be available to interested parties through a live audio webcast accessible through a link in the investor information section of Myriad’s website at www.myriad.com.
About Myriad Genetics
Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, EndoPredict, Vectra, GeneSight and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.
Media Contact: Ron Rogers (801) 584-3065 [email protected] Investor Contact: Scott Gleason (801) 584-1143 [email protected]
